Charles Schwab Investment Management Inc. Boosts Stock Position in TransMedics Group, Inc. $TMDX

Key Points

• Charles Schwab Investment Management Inc. increased its stake in TransMedics Group, Inc. by 2.3% to a total of 304,367 shares, valued at approximately $20.5 million.
• Several hedge funds have recently adjusted their positions in TransMedics, with GAMMA Investing LLC boosting its stake by an impressive 551.7% in the first quarter.
• Equities analysts are optimistic about TransMedics, with Canaccord Genuity and Oppenheimer raising their target prices to $142.00 and $150.00 respectively, suggesting strong market confidence in the stock.

Charles Schwab Investment Management Inc. lifted its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 2.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 304,367 shares of the company's stock after acquiring an additional 6,934 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.90% of TransMedics Group worth $20,478,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. NBC Securities Inc. purchased a new stake in TransMedics Group in the 1st quarter worth approximately $25,000. Hager Investment Management Services LLC increased its holdings in shares of TransMedics Group by 38.3% in the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock worth $50,000 after purchasing an additional 205 shares during the period. CWM LLC raised its position in shares of TransMedics Group by 20.1% in the first quarter. CWM LLC now owns 925 shares of the company's stock worth $62,000 after buying an additional 155 shares in the last quarter. GAMMA Investing LLC boosted its stake in TransMedics Group by 551.7% during the first quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock valued at $105,000 after buying an additional 1,324 shares during the period. Finally, Sava Infond d.o.o. boosted its stake in TransMedics Group by 46.7% during the first quarter. Sava Infond d.o.o. now owns 2,200 shares of the company's stock valued at $148,000 after buying an additional 700 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on TMDX shares. Canaccord Genuity Group upped their target price on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, July 15th. Oppenheimer upped their price objective on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 17th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Morgan Stanley lifted their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Finally, Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, TransMedics Group presently has a consensus rating of "Moderate Buy" and an average target price of $123.00.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 5,000 shares of the company's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total transaction of $632,250.00. Following the completion of the sale, the director directly owned 2,866 shares in the company, valued at $362,405.70. This represents a 63.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Anil P. Ranganath sold 686 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the transaction, the insider directly owned 13,955 shares in the company, valued at $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX opened at $118.81 on Friday. The stock's 50-day moving average is $122.11 and its 200 day moving average is $100.99. The stock has a market cap of $4.05 billion, a price-to-earnings ratio of 61.56 and a beta of 2.09. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. The business had revenue of $157.37 million for the quarter, compared to analysts' expectations of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business's quarterly revenue was up 37.7% on a year-over-year basis. During the same period last year, the business earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.